
    
      The investigators select patients of primary breast cancer whose hormone receptor is positive
      and accepted postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them
      with zoledronic acid 4mg intravenous infusion every six months until the end of the aromatase
      treatment. Assess the disease-free survival; overall survival; combination of security, as
      well as the situation of bone loss.
    
  